The challenges and trends of cell & gene therapies
Drug Discovery World
SEPTEMBER 6, 2022
Speaking about emerging opportunities, Carlo Russo, CEO of Genenta, says that whilst “immuno-oncology treatment has been very successful in treating patients suffering from blood cancer,” its success has been limited “by the durability of the responses”. billion, compared to $19.9 million price point per dose.
Let's personalize your content